Clinical characteristics of perimenopausal migraine and its correlation to hormonal levels
Abstract
BACKGROUND: Studies about perimenopausal migraine are limited. In this study, we aimed to explore the characteristics of perimenopausal migraine and to compare perimenopausal women with and without migraine in terms of the levels of Estradiol and Follicle-Stimulating Hormone (FSH). We also aimed to correlate migraine severity scores with Estradiol and FSH levels.
METHODS: A case-control study of 66 subjects divided as Group 1 (n = 22): migraine onset during perimenopause, Group 2 (n = 22) migraine onset before perimenopause, and Group 3 (n = 22) age-matched healthy controls. Perimenopausal women with any type of migraine (age 40-55 years) were eligible. We excluded secondary and other primary headaches, hormonal therapy and chronic illness. Subjects underwent a detailed history taking of headache and vasomotor symptoms, MIDAS and VAS scores. Measurement of Estradiol (E2) and FSH levels was done for all participants. Comparisons were done between group 1 and group 2 by migraine characteristics, vasomotor symptoms and Estradiol and FSH levels. Group 3 (control) was compared with both migraine groups 1 and 2 by vasomotor symptoms and Estradiol and FSH levels. Statistical analysis was performed by using SPSS 27th edition Statistical tests used include mean, median, count, Mann-Whitney U, Kruskal-Wallis test, Chi-squared test and the Spearman correlation test (The suitable test was chosen based on the type of variables and data, and the number of comparison groups).
RESULTS:…
How strong is the evidence?
Evidence Hub reads this as a case-control, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 66 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.